• Proprietary exosome platform with multiple research, diagnostic and therapeutic applications
• Clinical-stage ovarian cancer screening test and breast cancer monitoring test
• Preclinical-stage next-gen exosome therapeutic in development for triple-negative breast cancer

INOVIQ is a leading exosome company developing next-generation cancer diagnostics and therapeutics. The company's proprietary exosome platform underpins its research tools, diagnostics, and therapeutic pipeline. Key achievements in FY25 include establishing a global distribution partner for its exosome research tools, developing a highly accurate ovarian cancer screening test, and advancing a preclinical-stage exosome therapy for triple-negative breast cancer. Looking ahead, INOVIQ aims to partner its diagnostic programs, accelerate the development of its exosome therapeutics, and grow revenues. The company's three-year objectives include expanding its exosome research tools customer base, progressing the ovarian cancer screening test towards commercialization, generating in vivo data for its breast cancer exosome therapy, and partnering its breast cancer monitoring test. INOVIQ is well-positioned to establish itself as a leading exosome company with best-in-class diagnostics and therapeutics for cancer.